KAC36951
Colorimetric
Plasma, Serum
Quantitative
15.625-1,000 ng/ml
CV<20%
80-120%
2-8 ℃
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
Atlizumab, MRA / R-1569 / RHPM-1 / RO-4877533, CAS: 375823-41-9
Influence of anti-Spike protein antibody levels on tocilizumab efficacy in hospitalized patients with severe COVID-19 pneumonia: a post-hoc analysis of the COVACTA trial., PMID:40340657
A Comparison of the Immunogenicity of Intravenous BAT1806, a Tocilizumab Biosimilar, and Its Reference Product., PMID:40198544
Real-world experience with therapies for SARS-CoV-2: Lessons from the Italian COVID-19 studies., PMID:40071259
Sustained Interferon Signature Suppression With Anifrolumab in a Patient With STING-Associated Vasculopathy with Onset in Infancy Refractory to JAK Inhibitor and Dazukibart Therapy., PMID:40007227
Rheumatoid arthritis associated cytokines and therapeutics modulate immune checkpoint receptor expression on T cells., PMID:39981237
Long-term increase in soluble interleukin-6 receptor levels in convalescents after mild COVID-19 infection., PMID:39835136
Assessment of clinical benefit, cost and uptake of biosimilars versus reference biologics in immune-mediated inflammatory diseases in China., PMID:39697288
The development of therapeutics and vaccines against COVID-19., PMID:39637679
Pharmacokinetics and Safety of Intravenous Candidate Biosimilar CT-P47 and Reference Tocilizumab: A Randomized, Double-Blind, Phase 1 Study., PMID:39415551
Current and emerging pharmacotherapies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis-like syndrome due to CAR T cell therapy., PMID:38588525
Farnesoid X Receptor Protects Murine Lung against IL-6-promoted Ferroptosis Induced by Polyriboinosinic-Polyribocytidylic Acid., PMID:38300138
Rituximab, but not other biologics, impairs humoral immunity in patients with rheumatoid arthritis-a study using CoVariant protein arrays., PMID:37937178
Blocking IL-6 signaling improves glucose tolerance via SLC39A5-mediated suppression of glucagon secretion., PMID:37380017
COVID-19 therapy and vaccination: a clinical narrative review., PMID:36793450
Pharmacokinetics of a proposed tocilizumab biosimilar (MSB11456) versus US-licensed tocilizumab: results of a randomized, double-blind, single-intravenous dose study in healthy adults., PMID:36715299
Cancer-associated fibroblasts induce growth and radioresistance of breast cancer cells through paracrine IL-6., PMID:36635302
Care for adults with COVID-19: living guidelines from the National COVID-19 Clinical Evidence Taskforce., PMID:36150213
Immune-related adverse events of biological immunotherapies used in COVID-19., PMID:36091800
Alternative Biologic Therapy in Children Failing Conventional TNFα Inhibitors for Refractory, Noninfectious, Chronic Anterior Uveitis., PMID:35863492
Robust long-term immunity to SARS-CoV-2 in patients recovered from severe COVID-19 after interleukin-6 blockade., PMID:35816896
[Treatment of COVID-19]., PMID:35781447
Immunosuppressive treatments selectively affect the humoral and cellular response to SARS-CoV-2 in vaccinated patients with vasculitis., PMID:35736379
Autoantibodies Neutralizing Type I INFs May Be Associated with Efficacy of Tocilizumab in COVID-19 Pneumonia., PMID:35676568
Outcomes following SARS-CoV-2 infection in patients with primary and secondary immunodeficiency in the UK., PMID:35641155
Paracrine IL-6 Signaling Confers Proliferation between Heterogeneous Inflammatory Breast Cancer Sub-Clones., PMID:35565421
A Systematic Review Assessing the Underrepresentation of Cancer Patients in COVID-19 Trials., PMID:35447626
Could anakinra outmatch dexamethasone/tocilizumab in COVID-19?, PMID:35431536
TREATMENT OF MYASTHENIA GRAVIS PATIENTS WITH COVID-19: REVIEW OF THE LITERATURE., PMID:35282492
A guide to immunotherapy for COVID-19., PMID:35064248
The development of biologics to target SARS-CoV2: Treatment potential of antibodies in patient groups with poor immune response., PMID:34870159
ESCMID COVID-19 living guidelines: drug treatment and clinical management., PMID:34823008
High Induction of IL-6 Secretion From hUCMSCs Optimize the Potential of hUCMSCs and TCZ as Therapy for COVID-19-Related ARDS., PMID:34757857
Prevention of IL-6 signaling ameliorates toluene diisocyanate-induced steroid-resistant asthma., PMID:34332882
Clinical Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP)., PMID:34328629
Contemporary narrative review of treatment options for COVID-19., PMID:34240518
Can emapalumab be life saving for refractory, recurrent, and progressive cytokine storm caused by COVID-19, which is resistant to anakinra, tocilizumab, and Janus kinase inhibitors., PMID:34169908
Off-label Use of Itolizumab in Patients with COVID-19 ARDS: Our Clinical Experience in a Dedicated COVID Center., PMID:34045817
Current Overviews on COVID-19 Management Strategies., PMID:33966618
Application of systems biology-based in silico tools to optimize treatment strategy identification in Still's disease., PMID:33892792
Potential therapeutic and pharmacological strategies for SARS-CoV2., PMID:33688448
Cytokine Signature Induced by SARS-CoV-2 Spike Protein in a Mouse Model., PMID:33584719
Current treatment in COVID-19 disease: a rapid review., PMID:33569082
A Phase I Clinical Study Comparing the Tolerance, Immunogenicity, and Pharmacokinetics of Proposed Biosimilar BAT1806 and Reference Tocilizumab in Healthy Chinese Men., PMID:33569002
Potential COVID-19 Therapeutic Agents and Vaccines: An Evidence-Based Review., PMID:33511638
Interleukin-6 neutralization ameliorates symptoms in prematurely aged mice., PMID:33393189
Possible treatment and strategies for COVID-19: review and assessment., PMID:33336780
Tocilizumab inhibits IL-8 and the proangiogenic potential of triple negative breast cancer cells., PMID:33264466
Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium., PMID:33125391
Personalized Cytokine-Directed Therapy With Tocilizumab for Refractory Immune Checkpoint Inhibitor-Related Cholangiohepatitis., PMID:32956849
Convalescent plasma for pediatric patients with SARS-CoV-2-associated acute respiratory distress syndrome., PMID:32885904
Order: order@antibodysystem.com
Mail: support@antibodysystem.com
For research use only. Not for human or drug use.
Find out more about placing an order here
